Partner Linkage Tool for Team Grants: Bringing Biology to Cancer Prevention
The Team Grants: Bringing Biology to Cancer Prevention funding opportunity aims to unite interdisciplinary research teams to advance the biological and mechanistic understanding of cancer etiology, genesis, and risk, linked with host, lifestyle, environmental, social, and other factors, to identify new targets and approaches for cancer prevention, risk reduction, and early detection.
The Partner Linkage Tool aims to facilitate connections between applicants to support the formation of research teams and application development.
To be included in this Partner Linkage Tool, please complete this form. This form can be completed by researchers, knowledge users (e.g., people with lived and living experience, practitioners, policy makers), and applicant partners, who are interested in sharing information and/or establishing collaborations for this funding opportunity.
Note that completing this form is voluntary as it is not a requirement of the application process and does not confer any advantages in the evaluation and funding of applications. Furthermore, potential applicants are not required to contact those who have chosen to make their information available through the Partner Linkage Tool.
By completing and submitting this form, you are consenting to having your responses posted, uneditedFootnote *, and in the language of submission (English or French). You may request to have your information edited or removed at any time by sending a request to cihr.icr@uhn.ca. Requests for edits or removal of information will be actioned regularly. The information provided will be shared publicly in the table below and updated regularly.
Should you have any questions regarding this form or the tool, please email cihr.icr@uhn.ca.
Notice
The information is provided in the language in which it was submitted by the respondent.
| Contact Information | Stakeholder Category | Funding Pool of Interest | Research Area and Expertise | Additional Information |
|---|---|---|---|---|
|
Isabelle Plante |
Researcher |
|
My research program aims to determine the effects of exposure to endocrine disruptive compounds (EDCs) on mammary gland development and breast cancer, and to determine the toxicity mechanisms involved. To do so, we use in vivo models combined with innovative in vitro 3D models, as well as zebrafish. We also have projects involving occupational exposure in humans. The results obtained with these different types of models are analyzed by histological, proteomic, transcriptomic and functional approaches. |
|
|
Walid Houry |
Researcher |
|
My group has been studying the mitochondrial ClpP protease and its role in cancer, and has been developing compounds targeting the protease to be used as novel anticancers. We have been testing these compounds in breast cancers. However, the compounds also seem to be promising for glioblastomas. |
My group's expertise is in protein biochemistry and structural biology, cell biology, and drug discovery. I am interested in testing the ClpP-targeting compounds in animal models and patient tissue. As such, I am interested in collaborating with groups that have animal expertise as well as clinical expertise, and that have access to patient tissue samples. |
|
Talía Malagón |
|
|
Epidemiologist, health decision modeller, and population scientist specializing in cancer screening and early cancer detection, mostly in the context of cervical cancer. Research interests include:
|
I am looking to build connections and partner with other researchers as a co-applicant in an interdisciplinary team for this funding opportunity in research projects focused on cancer diagnosis and early detection/screening. I can contribute to research teams as an early career researcher (ECR) and as an expert in either pillar 3 (health services research) or pillar 4 (Social, cultural, environmental and population health research) to fulfill the requirements of this funding opportunity. |
|
Ahouehome sehouenou Albéric Candide |
Épidémiologiste titulaire d'une maitrise en quête d'une opportunité de projet doctoral |
|
Épidémiologie, biostatistique, Santé publique et imagerie médicale |
Je désire poursuivre un projet doctoral en épidémiologie avec potentiellement des chercheurs expérimentés en biostatistiques en lien avec les projets sur le cancer, l'intelligence artificielle, en biologie du cancer. |
|
Subburaj Ilangumaran |
Researcher |
|
|
We would like exploit our tissue-specific SOCS1 deficient mouse models that are more sensitive to develop liver and prostate cancers than wild type mice to assess the pro-carcinogenic effects of food additives and the antagonistic effects of dietary, probiotic and post-biotic interventions. We are specifically looking for
|
|
Alexander Baker, Ph.D. |
Early career researcher |
Breast cancer |
We develop advanced in vitro models to study breast cancer, emphasizing how extracellular matrix (ECM) composition affects drug responses and the immune system. Central to our approach is synthesizing biopolymers and incorporating cell-adhesive peptides to create 3D environments mimicking the tumor microenvironment. We leverage 3D tumor models, previously including patient-derived organoids (PDOs) and xenografts (PDXs), to explore tumor behavior and validate findings. Through drug screening, we aim to identify therapeutic targets and improve drug response predictions towards precision medicine. |
We aim to establish collaborations with experts in immunology, computational modeling, and bioinformatics to enhance the analysis of drug-immune interactions within our in vitro models. We also seek team members with expertise in advanced imaging techniques, and clinical oncology to integrate diverse perspectives into our research. Our proposed focus includes novel proteolysis targeting chimeras (PROTACs), investigating how ECM composition modulates metastasis, immune cell activity, and drug efficacy in breast cancer to identify biomarkers and therapeutic targets for personalized treatment. |
|
Hamid Ghaedi |
|
|
My research integrates bioinformatics, computational genomics, and multi-omics data analysis to uncover novel biomarkers and pathways in cancer prevention and progression. I specialize in analyzing bulk and single-cell RNA-seq datasets, developing scalable workflows for genomic data, and building predictive models using machine learning. My work supports clinical trials by identifying therapy-related transcriptional programs and linking genomic markers to patient outcomes. With expertise in cancer genomics and computational tools, I seek collaborative opportunities to advance precision approaches in cancer prevention and early detection. |
I am seeking to join a collaborative, multidisciplinary team where I can contribute my expertise in bioinformatics and cancer genomics. Earlier in 2024, I helped secure a $2.5M grant and currently lead bioinformatics analyses on bladder cancer single-cell RNA-seq and whole exome sequencing data. I aim to apply advanced computational approaches to uncover novel biomarkers and pathways for cancer prevention and early detection. I am eager to contribute to innovative, team-driven projects in this funding opportunity. |
|
Mitra Tabatabaee |
Early career researcher | General pool |
I am molecular biologist, who is looking for molecular mechanisms underlying cancer progression and metastasis, specifically in astrocytoma and gliomas. |
|
|
Paola Marignani |
Researcher |
|
Areas of expertise include single-cell RNAseq analysis in primary tumours and tumours from animal models. We apply computational analysis and machine learning algorithms for identifying unique genes and tumour heterogeneity. Areas of signalling expertise include cancer metabolism, LKB1/AMPK/mTOR signalling networks, HER2 receptor signalling, SMARCA4 signalling, mitochondria metabolism. Animal models include: spontaneous mouse models of HER2+ breast cancer, lung cancer and dementia models. |
|
|
Canadian Partnership Against Cancer |
Applicant partner | As the steward of the Canadian Strategy for Cancer Control (the Strategy), the Canadian Partnership Against Cancer (the Partnership) receives ongoing funding from Health Canada to work with provincial and territorial ministries of health and their cancer programs, health system leaders and clinicians, and people affected by cancer across Canada to implement the Strategy to improve cancer outcomes for all people in Canada. |
The Canadian Partnership Against Cancer's OncoSim is available for projects aimed at achieving the goals of the Canadian Strategy for Cancer Control. The OncoSim microsimulation model projects health and economic outcomes for various cancers, enabling users to create and compare scenarios with results that inform cancer service planning. In-kind support includes:
|
|
|
Providence Therapeutics |
Applicant partner | Providence Therapeutics (PTx) is an mRNA Medicines Platform company operating in the RNA field for 10 years. PTx has developed platforms for mRNA and lipid nanoparticle (LNP) medicines that stimulate immune responses to cancers and infectious diseases. Additionally, PTx is able to manufacture vaccines and therapeutics from personalized to pandemic scale. PTx's preclinical pipeline includes programs in oncology, infectious diseases, and animal health, developed both internally and with academic and industry partners. Furthermore, PTx has collaborations with UHN and OICR for research translation on the PTx platform. | Providence Therapeutics offers a comprehensive mRNA Medicines Platform to interested researchers. PTx is committed to leveraging the potential of mRNA technology for the development of innovative mRNA medicines. PTx invites researchers to utilize its proven mRNA platform and LNP technology to translate their discoveries into clinical applications. | |
|
Health Canada's Food and Nutrition Directorate |
Applicant partner | Ultra-processed foods |
Health Canada is the Federal department responsible for helping Canadians maintain and improve their health. Within Health Canada, the Food and Nutrition Directorate has the mandate to:
The Food and Nutrition Directorate includes the Bureau of Chemical Safety and Bureau of Nutritional Sciences. |
Health Canada is interested in projects that aim to better elucidate potential pathways by which ingredients or other substances in ultra-processed foods may affect biological mechanisms related to cancer risk or development. In-kind support may include:
|
|
Canadian Nuclear Laboratories |
Applicant partner | The Canadian Nuclear Laboratories (CNL) is Canada's premier nuclear science and technology organization, and a world leader in developing nuclear technology for peaceful and innovative applications. Using our unique expertise, we are restoring and protecting the environment, we are advancing clean energy technology, and our medical breakthroughs continue to improve the health of people around the world. CNL's unique Biological Research Facility and irradiation capabilities enable iconic long-term in vivo studies of impact of radiation on health. For 75 years, CNL has been at the forefront of innovation in nuclear medicine, radiopharmaceuticals, and low dose radiation research. |
CNL is interested in projects that aim to prevent cancer due to chronic exposure to low dose ionizing radiation that may happen in the environment, such as radon emission, in the workplace, or during repeated medical procedures. In-kind support may include:
|
|
|
Michelle Brazas |
|
General pool | The Canadian Bioinformatics Workshops (CBW) offered through Bioinformatics.ca focuses on training in leading technologies and the latest methods being used in computational biology to work with these data. These include high-throughput sequencing data, protein-protein interaction data, cancer data, metabolomics, epigenomics data and all the visual, statistical and command-line tools necessary to perform bioinformatics work. | The Canadian Bioinformatics Workshops (CBW) is constantly developing new workshops to facilitate research and skill development. CBW is open to working with applicants as the training collaborator should an application have a training component as a mechanism to "Strengthen and promote research capacity". |
|
Peter K Rogan |
|
|
We find and validate mutations and gene signatures that others cannot with advanced, patented genomic bioinformatic technologies for genomic medicine. Our software provides fully automated genome interpretation solutions for research, translational and clinical labs. Genome interpretation of exomes, gene panel, or complete genome uses the Shannon transcription factor and splicing pipelines, ASSEDA, and Veridical with the Cytognomix User Variation Database and Variant Effect Predictor. Our integrated suite of software products analyzes coding, non-coding, and copy number variants, and compares new results with existing or your own database. | Our expertise, publications and intellectual property cover a) Genome-Scale Variant Interpretation and analysis of all types of mutations in coding and non-coding regions including interpretation, comparison and management of genetic variant data; b) Automated radiation biodosimetry using images from metaphase scanning systems, identifying dicentric chromosomes, building biodosimetry calibration curves, and estimating exposures; c) Pharmacogenomic responses to chemotherapy drugs and radiation can be predicted by supervised machine learning of gene expression and copy number changes of relevant gene combinations. |
| Jacqueline Limoges jacqueline.limoges@athabascau.ca Athabasca University Toronto, Canada |
|
|
I lead a program of research and knowledge mobilization activities to support the integration of genomics into nursing education and practice. This research has identified: a) policy recommendations, b) strategies to support the equitable integration of genomics into practice, c) approaches to nursing workforce development d) strategic directions for cross sector, interprofessional and global genomics integration activities and e) leadership strategies for health system transformation for the genomic era. | I am interested in collaborating with interprofessional groups to support the integration of genomics into new care pathways, new mainstreaming models and other models of care to enhance the qualify, safety and accessibility of genomics. |
| Linda Chelico linda.chelico@usask.ca 306-966-4318 University of Saskatchewan Saskatoon, Canada |
|
|
The APOBEC3 enzymes are cytosine deaminases and cause mutations in 70% of cancer types. APOBEC3 enzymes normally act as host restriction factors to inhibit viruses. Despite these benefits of A3 enzymes for suppression of retroelements and viruses, there is evidence that there is a cost to this defense system in the form of A3-catalyzed deaminations that occur in our genomes during our lifetime. Our lab studies: (1) The influence of A3-induced mutations on the fate of tumor cells and non-tumorigenic epithelial cells using mouse xenograft models. (2) How interactions of A3 enzymes with other cellular proteins influence genomic stability. | I would like to establish collaborations with cancer centers that study somatic mutations in cancers where APOBEC3 enzymes may be responsible. I am a biochemist and molecular biologist focusing on enzyme-DNA interactions so I am also happy to contribute to research teams needing expertise to study the biochemistry of DNA repair proteins. |
- Date modified: